KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors

Table 1 Information of included studies

	Study	N	Trial	Drug	Tumor	Outcomes	MINORS	Reference
1	Ou et al. 2022	23	phase I/IB	Adagrasib	NSCLC, CRC, Others	ORR, DCR, PFS, OS	14	[12]
2	Negrao et al. 2023	25	phase I/IB	Adagrasib	NSCLC	ORR, DCR, PFS	14	[13]
3	Jänne et al. 2022	116	phase II	Adagrasib	NSCLC	ORR, DCR, PFS, OS	16	[14]
4	Yaeger et al. 2023	44	phase I-II	Adagrasib	CRC	ORR, DCR, PFS, OS	15	[15]
		32		Adagrasib + Cetuximab		ORR, DCR, PFS, OS
5	Hong et al. 2020	129	phase I	Sotorasib	NSCLC, CRC, Others	ORR, DCR, PFS	14	[16]
6	Skoulidis et al. 2021	124	phase II	Sotorasib	NSCLC	ORR, DCR, PFS, OS	16	[9]
7	Fakih et al. 2021	62	phase II	Sotorasib	CRC	ORR, DCR, PFS, OS	16	[17]
8	Strickler et al. 2023	38	phase I-II	Sotorasib	Others	ORR, DCR, PFS, OS	16	[18]
9	Langen et al. 2023	171	phase III	Sotorasib	NSCLC	ORR, DCR, PFS, OS	16	[19]
10	Desai et al. 2024	29	phase I/IB	Divarasib + Cetuximab	CRC	ORR, DCR, PFS	16	[20]
11	Stratmann et al. 2024	163	Retropective	Sotorasib	NSCLC	ORR, DCR, PFS, OS	14	[21]
12	Thummalapalli et al. 2023	105	Retropective	Sotorasib	NSCLC	PFS, OS	14	[22]
13	Ernst et al. 2024	71	Prospective	Sotorasib	NSCLC	PFS, OS	14	[23]

ISSN: 1479-5876